# A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

> **NCT05104463** · PHASE2 · COMPLETED · sponsor: **CuraSen Therapeutics, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Dementia

## Interventions

- **DRUG:** CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

## Key facts

- **NCT ID:** NCT05104463
- **Lead sponsor:** CuraSen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2023-12-20
- **Final completion:** 2024-02-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05104463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05104463, "A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05104463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*